Rezolute Inc
NASDAQ:RZLT
Intrinsic Value
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of RZLT.
Rezolute Inc's market capitalization is 116.1m USD.
RZLT stock price is 2.93 USD.
RZLT.
RZLT. Open DCF Valuation
RZLT. Open Relative Valuation
RZLT has upside potential of 237% compared to the average analyst price target.
Open Wall St Estimates
RZLT has negative Free Cash Flow for the last twelve months.
RZLT has negative Operating Income for the last twelve months.
RZLT has negative Net Income for the last twelve months.
RZLT's ROE (Return on Equity) has significantly increased in the last 3 years from -91% to -49%, and is approaching profitability.
RZLT's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 1 886% to -1 877%.
RZLT's ROE (Return on Equity) for the past 12 months is negative and is equal to -49%.
RZLT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 877%.
RZLT has negative three-year average ROE (Return on Equity): -74%. The company is not efficient at transforming stockholders' equity into net income.
RZLT has negative three-year average ROIC (Return on Invested Capital): -1 727%. The company is not efficient at using invested capital to generate operating income.
RZLT's short-term assets (96m USD) exceed its short-term liabilties (8m USD).
RZLT's long-term assets (102m USD) exceed its long-term liabilties (10m USD).
RZLT's D/E (Debt to Equity) is very low and is equal to 0.
RZLT's Altman Z-Score is very low and is equal to -3.77.
Fundamental Analysis
Rezolute Inc
Balance Sheet Decomposition
Rezolute Inc
| Current Assets | 96.1m |
| Cash & Short-Term Investments | 92.6m |
| Other Current Assets | 3.5m |
| Non-Current Assets | 6.1m |
| Long-Term Investments | 3.4m |
| PP&E | 2.2m |
| Other Non-Current Assets | 464k |
| Current Liabilities | 8m |
| Accounts Payable | 3.6m |
| Accrued Liabilities | 3m |
| Other Current Liabilities | 1.4m |
| Non-Current Liabilities | 2.4m |
| Other Non-Current Liabilities | 2.4m |
Earnings Waterfall
Rezolute Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-62.5m
USD
|
|
Operating Income
|
-62.5m
USD
|
|
Other Expenses
|
5.7m
USD
|
|
Net Income
|
-56.8m
USD
|
Free Cash Flow Analysis
Rezolute Inc
RZLT Profitability Score
Profitability Due Diligence
Rezolute Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Rezolute Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
RZLT Solvency Score
Solvency Due Diligence
Rezolute Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Rezolute Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RZLT Price Targets Summary
Rezolute Inc
According to Wall Street analysts, the average 1-year price target for
RZLT
is 9.86 USD
with a low forecast of 7.07 USD and a high forecast of 14.7 USD.
Ownership
RZLT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
RZLT Price
Rezolute Inc
| Average Annual Return | -13.18% |
| Standard Deviation of Annual Returns | 74.83% |
| Max Drawdown | -97% |
| Market Capitalization | 116.1m USD |
| Shares Outstanding | 40 127 600 |
| Percentage of Shares Shorted | 1.43% |
Company Profile
Rezolute Inc
Country
Industry
Market Cap
Dividend Yield
Description
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 26 full-time employees. The company went IPO on 2011-12-23. The firm's lead clinical asset, RZ358, is an antibody therapy in Phase II b development as a potential treatment for Congenital Hyperinsulinism (CHI), an ultra-rare pediatric genetic disorder. Its second clinical asset, RZ402, is a selective and potent Plasma Kallikrein Inhibitor (PKI) being developed as a potential oral therapy for the chronic treatment of Diabetic Macular Edema (DME), is in Phase I development. The clinical study conducting by the Company is called RIZE - An open-label multiple-dose study of RZ358 in Patients with Congenital Hyperinsulinism.
You don't have any saved screeners yet
